静脉滴注重组人血管内皮抑素联合动脉灌注化疗治疗晚期恶性肿瘤的临床观察  

Intravenous drip transfusion of recombinant human endostatin combined with arterial infusion chemotherapy for the treatment of advanced carcinomas: a clinical observation

作　　者：王革芳[1] 程永德[1] 王咏梅[1] 杜爱民[1] 毛勇[1] 陆海宇[1] 姜程远[1] 陆海洲[1] 王蕾作 

机构地区：[1]上海解放军第八五医院内一科,200052

出　　处：《介入放射学杂志》2009年第4期270-273,共4页Journal of Interventional Radiology

摘　　要：目的探讨静脉滴注重组人血管内皮抑素联合动脉灌注化疗治疗晚期恶性肿瘤的疗效及安全性。方法选取41例晚期恶性肿瘤患者入组研究,分为治疗组和对照组,均给予相应的肿瘤供血动脉灌注化疗,治疗组在灌注化疗后当天开始给予重组人血管内皮抑素静脉滴注治疗,连用14d,间隔7d为1个周期,对照组仅行动脉灌注化疗治疗,于2个治疗周期后比较疗效和生活质量评分,同时比较不良反应。结果重组人血管内皮抑素治疗组治疗后疾病控制率、K氏评分显著升高,差异有统计学意义(P<0.05);有效率和不良反应与对照组差异无统计学意义(P>0.05)。结论采用静脉滴注重组人血管内皮抑素联合动脉灌注化疗治疗晚期恶性肿瘤,患者的疾病控制率和生活质量有明显的提高,而治疗相关不良反应不大,值得临床推广及进一步研究。Objective To discuss the clinical effects and the safety of intravenous drip transfusion of recombinant human endostatin combined with arterial infusion chemotherapy for the treatment of advanced carcinomas. Methods Forty-one patients with advanced carcinomas were enrolled in this study. The patients were divided into study group and control group. All patients underwent relevant infusion chemotherapy via the tumor-feeding artery. At the same day when the arterial infusion chemotherapy was completed, patients in study group stated to receive intravenous drip transfusion of recombinant human endostatin, which lasted for 14 days and, then, broke for 7 days （regarded as one therapeutic cycle）. No additional treatment was given to the patients in control group. After two therapeutic cycles, the clinical effect was evaluated with RE-CIST criteria and the living quality was assessed with Karnofsky scoring. The adverse effect was compared between two groups. Results The control rate of disease and the Karnofsky score were significantly higher in study group than thase in control group （P 〈 0.05 ）, while no significant difference in overall effective rate （CR and PR） and in adverse effect rate existed between two groups （P 〉 0.05 ）. Conclusion For the treatment of advanced carcinomas, intravenous drip transfusion of recombinant human endostatin combined with arterial infusion chemotherapy can markedly improve patient＇s living quality and disease control rate, besides, this therapy carries few adverse effects. Therefore, it is well worth making the effort to popularize this technique in clinical practice.

关 键 词：重组人血管内皮抑素 动脉灌注化疗 晚期恶性肿瘤 抗肿瘤血管形成 

分 类 号：R730.51[医药卫生—肿瘤]